MedTrace Logo

Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and Photodamage

NCT07053852 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-01-02

No results posted yet for this study

Summary

To provide a treatment of both actinic keratoses and photodamage within one treatment.

Conditions

  • Actinic Keratoses
  • Photodamage

Interventions

DRUG

Ameluz

broad band light (BBL) with the use of Ameluz

DEVICE

Sciton HEROic

Each subject will receive 2 treatments of photodynamic therapy using Ameluz and HEROic BBL to treat facial AK and signs of photodamage.

Sponsors & Collaborators

  • Sciton

    collaborator INDUSTRY

  • Biofrontera Bioscience GmbH

    collaborator INDUSTRY

  • Sherrif Ibrahim

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-27
Primary Completion
2025-12-29
Completion
2025-12-29
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07053852 on ClinicalTrials.gov